• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

University and Boehringer Ingelheim provide free access to PROTAC compound on opnMe.com

Bioengineer by Bioengineer
January 7, 2019
in Biology
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Boehringer Ingelheim to make BET degrader compound MZ 1 available through its opnMe.com portal

IMAGE

Credit: University of Dundee

  • Boehringer Ingelheim to make BET degrader compound MZ 1 available through its opnMe.com portal
  • Support of open access to boost progress in biomedical and drug discovery research
  • MZ 1 compound created at the University of Dundee is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal

A PROTAC COMPOUND developed at the University of Dundee is being made available free of charge by the pharmaceutical company Boehringer Ingelheim through their scientific crowdsourcing platform opnMe.com. The opnMe portal provides free and open access to selected molecules for the scientific community aiming at accelerating research initiatives that can benefit patients with high unmet medical need.

MZ 1 is a benchmark molecule, one of a new class of `PROTAC degraders’, which has helped to open up new research in therapeutic areas as diverse as oncology, immunology and respiratory diseases. This particular compound triggers the intracellular destruction of BET proteins, inducing preferential removal of BRD4 over BRD2 and BRD3 in cells.

PROTACs (PROteolysis TArgeting Chimeric molecules) are designed to harness the cell’s natural disposal system (the ubiquitin-proteasome) to specifically remove disease causing proteins. They do this by triggering the labelling of these as “expired” proteins, which the proteasome then removes. This opens up new opportunities to target disease mechanisms that have been difficult to reach.

Professor Alessio Ciulli has led the development and characterisation of MZ 1 at his laboratory in the School of Life Sciences at the University of Dundee. He said, “This is a major decision by Boehringer Ingelheim that will benefit scientific research and help us get closer to our ultimate aim of drugging what was previously considered undruggable, providing the opportunity to create new drugs to treat some terrible diseases.”

By making the compound freely available on their opnMe.com portal, Boehringer Ingelheim is providing a tool to researchers around the world which will make it easier and quicker to develop experiments that could in the end benefit patients with high unmet medical need.

Professor Ciulli said, “There is already more and more research taking place in the area of PROTACs and making the compound available in this way will enable many cell biologists, cancer biologists and drug discoverers alike to carry out experiments they would not have been able to pursue previously.”

Professor Ciulli and colleagues at Dundee first disclosed MZ 1 in 2015, revealing the potential to offer a super-targeted method of destroying unwanted proteins. In 2017, they provided the field with the first ever crystal structure of a PROTAC ternary complex. This breakthrough discovery revealed the molecular detail of how MZ 1 acts as a degrader, causing neutralising proteins to bind tightly to their bad neighbour and act against it, starting a cascade process of degradation. More recent work by Professor Ciulli and colleagues has further characterised the cellular activity and mode of action of MZ 1, also in vivo.

Boehringer Ingelheim has worked in collaboration with Professor Ciulli’s lab at the University of Dundee since 2016 with the aim to develop a novel class of medicines that target disease causing proteins for degradation.

The collaboration brings together the expertise of Professor Ciulli, one of the pioneers in the field of PROTACs, with Boehringer Ingelheim’s expertise in drug discovery and clinical development of new therapeutic agents.

###

Notes to editors

About the University of Dundee

The University of Dundee is one of the UK’s leading institutes for medical and life sciences research. Dundee was the top rated university in the UK for biological sciences in the most recent Research Excellence Framework.
Research intensity is matched by teaching excellence, with a Gold Award in the UK Teaching Excellence Framework, and one of the best student experiences in the UK.

Discover more about Dundee at http://www.dundee.ac.uk or follow us @dundeeuni

About opnMe.com

opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives and enable new disease biology in areas of high unmet medical need by sharing well-characterized, best-in-class, pre-clinical tool compounds. The MZ 1 degrader belongs to our ‘Molecules 2 Order’ program, which offers molecules free of charge. In addition, for our Molecules 4 Collaboration we are inviting scientists from around the world to propose novel research and funding proposals to explore its biology in the context of diseases. If your proposal is selected, the science will be developed together with Boehringer Ingelheim scientists as part of a bi-lateral collaboration.

Media Contact
Roddy Isles
[email protected]
44-138-238-4910

Tags: BiochemistrycancerChemistry/Physics/Materials SciencesMolecular BiologyPharmaceutical SciencePharmaceutical SciencesPharmaceutical/Combinatorial Chemistry
Share12Tweet8Share2ShareShareShare2

Related Posts

Turtle Meat Trade in Indonesia: Minimal Economic Impact

Turtle Meat Trade in Indonesia: Minimal Economic Impact

September 7, 2025
Winter Waterbirds Adapt to Severe Drought Challenges

Winter Waterbirds Adapt to Severe Drought Challenges

September 7, 2025

Honey Bee Gene Expression Altered by Electric Fields

September 7, 2025

Porcine Placenta Peptide Boosts Hair Health: Studies

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.